Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05433337 · ClinicalTrials.gov registry record · NA

Prospective Study to Evaluate a Digital Regimen for Fibromyalgia Management: An Extension Study

A NA study of Fibromyalgia, sponsored by Swing Therapeutics.

Completed
Registry status
NA
Development phase
60
Enrollment target
1
Study location

NCT05433337 is a NA study of Fibromyalgia that has completed, run by Swing Therapeutics. The registered enrollment target is 60 participants, below the 178-participant average among 76 other Fibromyalgia trials with a reported enrollment target (66% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05433337, a NA study of Fibromyalgia, has completed, sponsored by Swing Therapeutics.

COMPLETED
Registry status
NA
Development phase
60 participants
Enrollment target
1
Study location

Study Summary

This study is designed as a 9-month extension of the original study (PROSPER-FM). The purpose of the extension study is to assess the long-term (up to 1 year) response to a digital therapy in the treatment of fibromyalgia.

Conditions Studied

Interventions

  • DEVICE Digital ACT

Study Locations (1)

California

  • Swing Therapeutics - San Francisco

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2022-06-08
Est. Completion 2024-03-05
Phase NA

Sponsor

Swing Therapeutics

6 total trials

What the Registry Record Tells You About NCT05433337

The ClinicalTrials.gov registry entry for NCT05433337 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 178-participant average among 76 other Fibromyalgia trials with a reported enrollment target (66% lower). The listed sponsor is Swing Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Fibromyalgia appearing as the primary indexed condition, and to 1 intervention - of which Digital ACT is the first listed.

NCT05433337 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT05433337 about?

NCT05433337 is a clinical study titled "Prospective Study to Evaluate a Digital Regimen for Fibromyalgia Management: An Extension Study". This study is designed as a 9-month extension of the original study (PROSPER-FM). The purpose of the extension study is to assess the long-term (up to 1 year) response to a digital therapy in the treatment of fibromyalgia.

What is the current status of trial NCT05433337?

This trial is currently completed. It is a NA study. The enrollment target is 60 participants. The study started on 2022-06-08. Estimated completion is 2024-03-05.

What conditions does trial NCT05433337 study?

This clinical trial studies the following conditions: Fibromyalgia.

What interventions are being tested in trial NCT05433337?

The interventions under investigation include: Digital ACT (DEVICE).

Who is sponsoring clinical trial NCT05433337?

This trial is sponsored by Swing Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05433337 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Fibromyalgia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.